Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.76 |
| ▸ | CA2 | P00918 | 3/20 | 0.76 |
| ▸ | CA9 | Q16790 | 3/20 | 0.76 |
| ▸ | CA1 | P00915 | 2/20 | 0.76 |
| ▸ | GAA | P10253 | 7/20 | 0.73 |
| ▸ | POLB | P06746 | 2/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28696236 | 0.85 | CA12 (0.77) | CA12CA2CA9CA1GAA | |
| Diphenylurea SCHEMBL27302793 | 0.82 | MEN1 (0.81) | GAAPOLBSMN1; SMN2L3MBTL1MAPT | |
| SCHEMBL25870930 | 0.81 | CA12 (0.72) | CA12CA2CA9CA1GAA | |
| SCHEMBL26104435 | 0.81 | GAA (0.65) | CA12CA2CA9CA1GAA | |
| SCHEMBL11055960 | 0.80 | MEN1 (0.85) | GAAPOLBSMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL22124552 | 0.80 | CA2 (0.72) | CA12CA2CA9CA1GAA | |
| SCHEMBL7776322 | 0.79 | FLT1 (0.64) | CA12CA2CA9CA1GAA | |
| SCHEMBL7776164 | 0.79 | FLT1 (0.64) | CA12CA2CA9CA1GAA | |
| SCHEMBL23069044 | 0.77 | MEN1 (0.73) | GAAPOLBSMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL19472794 | 0.77 | ALDH1A1 (0.71) | CA2CA9CA1GAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174470-A1 | COMPOUND AS A UBR BOX DOMAIN LIGAND | AUTOTAC INC. (KR) | 2023-06-08 | — | — | US | disclosed |
| WO-2023074936-A1 | BIFUNCTIONAL COMPOUND USING UBR BOX DOMAIN-BINDING LIGAND | 주식회사 오토텍바이오 | 2023-05-04 | — | — | WO | disclosed |
| CN-115715285-A | Compounds as UBR box domain ligands | 奧土择破利悟 | 2023-02-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174470-A1 | COMPOUND AS A UBR BOX DOMAIN LIGAND | UBR4, UBQLN2, UBTF | CA12 4586/4885CA2 4852/4885CA9 4699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.